Sun, Yang
Hu, Lu http://orcid.org/0000-0002-1594-8828
Tao, Zhipeng http://orcid.org/0000-0002-9582-6950
Jarugumilli, Gopala K.
Erb, Hannah
Singh, Alka
Li, Qi
Cotton, Jennifer L. http://orcid.org/0000-0003-0106-1801
Greninger, Patricia http://orcid.org/0000-0001-9110-7695
Egan, Regina K.
Tony Ip, Y. http://orcid.org/0000-0003-4370-7906
Benes, Cyril H.
Che, Jianwei
Mao, Junhao
Funding for this research was provided by:
Antidote foundation for the cure of cancer, postdoc fellowship
Melanoma Research Alliance (postdoc fellowship)
Wellcome Trust (102696)
U.S. Department of Health & Human Services | National Institutes of Health (R01DK127180, R01DK127207)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA219814, R01CA238270)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 6 July 2021
Accepted: 28 October 2022
First Online: 8 November 2022
Competing interests
: X.W. has a financial interest in Tasca Therapeutics, which is developing small molecule modulators of TEAD palmitoylation and transcription factors. Dr. Wu’s interests were reviewed and are managed by Mass General Hospital, and Mass General Brigham in accordance with their conflict of interest policies. The remaining authors declare no competing interests.